At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 300 enrolled
Drug / intervention
TV-45070 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia.
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Feb 19, 2015·Updated Nov 9, 2021
In Brief
A Phase 2 clinical trial evaluating TV-45070 and Placebo for Postherpetic Neuralgia. Completed, enrolled 300 participants across 77 sites.
Detailed Summary
This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostherpetic Neuralgia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartFeb 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedFeb 19, 2015
Enrollment StartFeb 26, 2015
Primary CompletionMay 9, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.4 years ago
Interventions
TV-45070drug
TV-45070 is an ointment applied topically twice daily to area of pain.
Placebodrug
The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.